

<b>Department of Origin:</b> Integrated Healthcare Services	<b>Effective Date:</b> 12/06/22
<b>Approved by:</b> Medical Policy Quality Management Subcommittee	<b>Date Approved:</b> 12/06/22
<b>Clinical Policy Document:</b> Fetal Procedures In Utero	<b>Replaces Effective Clinical Policy Dated:</b> 12/07/21
<b>Reference #:</b> MC/G017	<b>Page:</b> 1 of 4

**PURPOSE:**

The intent of this clinical policy is to ensure services are medically necessary.

Please refer to the member’s benefit document for specific information. To the extent there is any inconsistency between this policy and the terms of the member’s benefit plan or certificate of coverage, the terms of the member’s benefit plan document will govern.

**POLICY:**

Benefits must be available for health care services. Health care services must be ordered by a provider. Health care services must be medically necessary, applicable conservative treatments must have been tried, and the most cost-effective alternative must be requested for coverage consideration.

**GUIDELINES:**

Medical Necessity Criteria – Must satisfy any of the following: I or II

- I. Fetal surgery in utero for any of the following indications: A – I
  - A. Ablation of anastomotic vessels in acardiac twins; or
  - B. Insertion of pleuro-amniotic shunt for fetal pleural effusion; or
  - C. Laser ablation or occlusion of anastomotic vessels in early, severe twin-twin transfusion syndrome; or
  - D. Removal of sacrococcygeal teratoma; or
  - E. Repair of myelomeningocele; or
  - F. Resection of malformed pulmonary tissue, or placement of a thoraco-amniotic shunt as a treatment of any of the following: 1 or 2
    - 1. Congenital cystic adenomatoid malformation (CCAM); or
    - 2. Extralobar pulmonary sequestration (EPS).
  - G. Thoracoamniotic shunt for pleural effusions; or
  - H. Twin reversed arterial perfusion (TRAP); or
  - I. Vesico-amniotic shunting as a treatment of urinary tract obstruction.
- II. Serial amnioreduction for twin-to-twin transfusion syndrome – must satisfy all of the following: A – D
  - A. Women after 26 weeks of gestation; and
  - B. Evidence of abnormal blood flow documented by Doppler studies in one or both fetuses; and
  - C. Evidence of polyhydramnios in the recipient fetus; and

<b>Department of Origin:</b> Integrated Healthcare Services	<b>Effective Date:</b> 12/06/22
<b>Approved by:</b> Medical Policy Quality Management Subcommittee	<b>Date Approved:</b> 12/06/22
<b>Clinical Policy Document:</b> Fetal Procedures In Utero	<b>Replaces Effective Clinical Policy Dated:</b> 12/07/21
<b>Reference #:</b> MC/G017	<b>Page:</b> 2 of 4

D. Donor fetus is oligohydramniotic.

**EXCLUSIONS (not limited to):**

Refer to member's Certificate of Coverage or Summary Plan Description

The following are considered investigative (see Investigative List): I – III

- I. Fetal in-utero surgery for any of the following indications: A – I
  - A. Fetal aortic valvuloplasty
  - B. Fetoscopic laser ablation for type 2 vasa previa
  - C. Shunting for the treatment of fetal cerebral ventriculomegaly
  - D. Treatment of amniotic band syndrome
  - E. Treatment of aqueductal stenosis (ie, hydrocephalus)
  - F. Treatment of cleft lip and/or cleft palate
  - G. Treatment of congenital heart disease (eg, mitral valve dysplasia)
  - H. Treatment of fetal hydronephrosis
  - I. Treatment of gastroschisis
- II. Stem cell transplantation in utero
- III. Gene therapy in utero

<b>Department of Origin:</b> Integrated Healthcare Services	<b>Effective Date:</b> 12/06/22
<b>Approved by:</b> Medical Policy Quality Management Subcommittee	<b>Date Approved:</b> 12/06/22
<b>Clinical Policy Document:</b> Fetal Procedures In Utero	<b>Replaces Effective Clinical Policy Dated:</b> 12/07/21
<b>Reference #:</b> MC/G017	<b>Page:</b> 3 of 4

Prior Authorization: Yes, per network provider agreement

Precertification: Yes

**CODING:**

CPT® or HCPCS

- 59072 Fetal umbilical cord occlusion, including ultrasound guidance
- 59076 Fetal shunt placement, including ultrasound guidance
- 59897 Unlisted fetal invasive procedure, including ultrasound guidance, when performed
- S2400 Repair, diaphragmatic hernia in the fetus using temporary tracheal occlusion, procedure performed in utero
- S2401 Repair, urinary tract obstruction in the fetus, procedure performed in utero
- S2402 Repair, congenital cystic adenomatoid malformation in the fetus, procedure performed in utero
- S2403 Repair, extralobar pulmonary sequestration in the fetus, procedure performed in utero
- S2404 Repair, myelomeningocele in the fetus, procedure performed in utero
- S2405 Repair, sacrococcygeal teratoma in the fetus, procedure performed in utero
- S2409 Repair, congenital malformation of fetus, procedure performed in utero, not otherwise classified
- S2411 Fetoscopic laser therapy for treatment of twin-twin transfusion syndrome

CPT codes copyright 2022 American Medical Association. All Rights Reserved. CPT is a trademark of the AMA. The AMA assumes no liability for the data contained herein.

**REFERENCES:**

1. Integrated Healthcare Services Process Manual: UR015 Use of Medical Policy and Criteria
2. Clinical Policy: MP/C009 Coverage Determination Guidelines
3. American College of Obstetricians and Gynecologists (ACOG). ACOG Committee Opinion. Maternal-Fetal Surgery for Myelomeningocele. Number 720, September 2017. Reaffirmed 2022. Retrieved from <https://www.acog.org/clinical/clinical-guidance/committee-opinion>. Accessed 09-27-22.
4. American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin. Neural Tube Defects. Number 187, December 2017 (Reaffirmed 2021). Retrieved from <https://www.acog.org/clinical/clinical-guidance/practice-bulletin>. Accessed 09-27-22.
5. American College of Obstetricians and Gynecologists (ACOG). ACOG Committee Opinion. Maternal-Fetal Intervention and Fetal Care Centers. Number 501, August 2011 (Reaffirmed 2020). Retrieved from <https://www.acog.org/clinical/clinical-guidance/committee-opinion>. Accessed 09-27-22.
6. Baskin LS. Fetal hydronephrosis: Etiology and prenatal management. (Topic 6099, Version 42.0; last updated: 12/02/2021). In: Wilkie L, ed. *UpToDate*. Waltham, Mass.: UpToDate; 2019. [www.uptodate.com](http://www.uptodate.com). Accessed 09-27-22.
7. Bulas DI, Egloff A. Bronchopulmonary sequestration: Prenatal diagnosis and management. (Topic 13515, Version 22.0; last updated: 06/16/22) In: Barss VA, ed. *UpToDate*. Waltham, Mass.: UpToDate; 2019. [www.uptodate.com](http://www.uptodate.com). Accessed 09-27-22.
8. Egler RA, Levine D, Wilkins-Haug L. Sacrococcygeal teratoma. (Topic 5200, Version 26.0; last updated: 07/26/22) In: Eichler AF, Barss VA, eds. *UpToDate*. Waltham, Mass.: UpToDate; 2020. [www.uptodate.com](http://www.uptodate.com). Accessed 09-27-22.
9. Egloff A, Bulas DI. Congenital pulmonary airway malformation: Prenatal diagnosis and management. (Topic 14207, Version 33.0; last updated: 04/29/22) In: Barss VA, ed. *UpToDate*. Waltham, Mass.: UpToDate; 2020. [www.uptodate.com](http://www.uptodate.com). Accessed 09-27-22.

<b>Department of Origin:</b> Integrated Healthcare Services	<b>Effective Date:</b> 12/06/22
<b>Approved by:</b> Medical Policy Quality Management Subcommittee	<b>Date Approved:</b> 12/06/22
<b>Clinical Policy Document:</b> Fetal Procedures In Utero	<b>Replaces Effective Clinical Policy Dated:</b> 12/07/21
<b>Reference #:</b> MC/G017	<b>Page:</b> 4 of 4

10. Miller R. Diagnosis and management of twin reversed arterial perfusion (TRAP) sequence. (Topic 14205, Version 28.0; last updated: 05/17/22) In: Barss VA, ed. *UpToDate*. Waltham, Mass.: UpToDate; 2020. [www.uptodate.com](http://www.uptodate.com). Accessed 09-27-22.
11. Papanna R, Bergh E. Twin-twin transfusion syndrome: Management and outcome. (Topic 6793, Version 90.0; last updated: 08/10/22) In: Barss VA, ed. *UpToDate*. Waltham, Mass.: UpToDate; 2020. [www.uptodate.com](http://www.uptodate.com). Accessed 09-27-22.
12. Philips III JB. Approach to the neonate with pleural effusions. (Topic 88437, Version 14.0; last updated: 06/24/2020) In: Kim MS, ed. *UpToDate*. Waltham, Mass.: UpToDate; 2020. [www.uptodate.com](http://www.uptodate.com). Accessed 09-27-22.
13. Society for Maternal-Fetal Medicine (SMFM). SMFM Consult Series #46: Evaluation and management of polyhydramnios. 2018. Retrieved from [https://www.ajog.org/article/S0002-9378\(18\)30589-1/pdf](https://www.ajog.org/article/S0002-9378(18)30589-1/pdf). Accessed 09-27-22.
14. Society for Maternal-Fetal Medicine (SMFM), Norton ME, Chauhan SP, et al. Society for maternal-fetal medicine (SMFM) clinical guideline #7: nonimmune hydrops fetalis. *Am J Obstet Gynecol*. 2015 Feb;212(2):127-39. Retrieved from: <https://www.smfm.org/publications/185-nonimmune-hydrops-fetalis>. Accessed 09-27-22.

**DOCUMENT HISTORY:**

<b>Created Date:</b> 10/07/20
<b>Reviewed Date:</b> 09/09/21, 09/07/22
<b>Revised Date:</b> 09/30/21

## Nondiscrimination & Language Access Policy

Aspirus Health Plan, Inc. complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. *We* do not exclude people or treat them differently because of race, color, national origin, age, disability, or sex.

*We* will:

- Provide free aids and services to people with disabilities to communicate effectively with us, such as:
  - Qualified sign language interpreters
  - Written information in other formats (large print, audio, accessible electronic formats, other formats)
- Provide free language services to people whose primary language is not English, such as:
  - Qualified interpreters
  - Information written in other languages

If *you* need these services, contact *us* at the phone number shown on the inside cover of this *COC*, *your* id card, or [aspirushealthplan.com](http://aspirushealthplan.com).

If *you* believe that *we* have failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, *you* can file a grievance with:

Nondiscrimination Grievance Coordinator  
Aspirus Health Plan, Inc.  
PO Box 1062  
Minneapolis, MN 55440  
Phone: 1. 866.631.5404 (TTY: 1.866.631.8597)  
Fax: 763.847.4010  
Email: [customerservice@aspirushealthplan.com](mailto:customerservice@aspirushealthplan.com)

*You* can file a grievance in person or by mail, fax, or email. If *you* need help filing a grievance, the Nondiscrimination Grievance Coordinator is available to help *you*.

*You* can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>, or by mail or phone at:

U.S. Department of Health and Human Services  
200 Independence Avenue, SW  
Room 509F, HHH Building  
Washington, D.C. 20201  
1-800-368-1019, 800-537-7697 (TDD)

Complaint forms are available at <http://www.hhs.gov/ocr/office/file/index.html>.

## Language Assistance Services

**Albanian:** KUJDES: Nëse flitni shqip, për ju ka në dispozicion shërbime të asistencës gjuhësore, pa pagesë. Telefononi në 1.866.631.5404 (TTY: 1.866.631.8597).

تنبيه: إذا كنت تتحدث اللغة العربية، فإن خدمات المساعدة اللغوية 1.866.631.5404 (رقم هاتف الصم والبك : 1.866.631.8597) متاحة لك مجاناً. اتصل بن اعلى رقم الهاتف  
**Arabic**

**French:** ATTENTION : Si vous parlez français, des services d'aide linguistique vous sont proposés gratuitement. Appelez le 1.866.631.5404 (ATS : 1.866.631.8597).

**German:** ACHTUNG: Wenn Sie Deutsch sprechen, stehen Ihnen kostenlos sprachliche Hilfsdienstleistungen zur Verfügung. Rufnummer: 1.866.631.5404 (TTY: 1.866.631.8597).

**Hindi:** \_यान द\_ : य\_द आप िहंदी बोलते ह\_ तो आपके िलए मु\_त म\_ भाषा सहायता सेवाएं उपल\_ध ह\_। 1-800-332-650 (TTY: 1.866.631.8597) पर कॉल कर\_।

**Hmong:** LUS CEEV: Yog tias koj hais lus Hmoob, cov kev pab txog lus, muaj kev pab dawb rau koj. Hu rau 1.866.631.5404 (TTY: 1.866.631.8597).

**Korean:** 주의: 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다. 1.866.631.5404 (TTY: 1.866.631.8597) 번으로 전화해 주십시오.

**Polish:** UWAGA: Jeżeli mówisz po polsku, możesz skorzystać z bezpłatnej pomocy językowej. Zadzwoń pod numer 1.866.631.5404 (TTY: 1.866.631.8597).

**Russian:** ВНИМАНИЕ: Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода. Звоните 1.866.631.5404 (телетайп: 1.866.631.8597).

**Spanish:** ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1.866.631.5404 (TTY: 1.866.631.8597).

**Tagalog:** PAUNAWA: Kung nagsasalita ka ng Tagalog, maaari kang gumamit ng mga serbisyo ng tulong sa wika nangwalang bayad. Tumawag sa 1.866.631.5404 (TTY: 1.866.631.8597).

**Traditional Chinese:** 注意：如果您使用繁體中文，您可以免費獲得語言援助服務。請致電 1.866.631.5404 (TTY : 1.866.631.8597)

**Vietnamese:** CHÚ Ý: Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn. Gọi số 1.866.631.5404 (TTY: 1.866.631.8597).

**Pennsylvania Dutch:** Wann du Deitsch (Pennsylvania German / Dutch) schwetzsch, kannscht du mitaus Koschte ebbergricke, ass dihr helft mit die englisch Schprooch. Ruf selli Nummer uff: Call 1.866.631.5404 (TTY: 1.866.631.8597).

**Lao:** ໂປດຊາບ: ຖ້າວ່າ ທ່ານເວົ້າພາສາ ລາວ, ການບໍລິການຊ່ວຍເຫຼືອດ້ານພາສາ, ໂດຍບໍ່ເສັຽຄ່າ, ແມ່ນມີພ້ອມໃຫ້ທ່ານ. ໂທສ 1.866.631.5404 (TTY: 1.866.631.8597).